|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells.
|
29617357 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
|
29655686 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Upregulation or the constitutive activation of epidermal growth factor receptor (EGFR) is a hallmark of osteosarcoma.
|
31404298 |
2019 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, PKC can be activated by several receptor tyrosine kinases implicated in osteosarcoma, including the ERBB family (EGFR, Her-2 and Her-4 in osteosarcoma), IGF1R, FGF, and others.
|
24924170 |
2014 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> functional assays demonstrated that targeting IGF-IR and EGFR didn't affect osteosarcoma cell viability, but inhibited ligand-activated intracellular signaling and cell migratory capacity.
|
28744395 |
2017 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
|
9108440 |
1997 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we summarized the roles and expression of ErbB family in OS and the current development of ErbB-targeted therapeutic strategies including chemotherapies and immunotherapies for OS treatment.
|
30353245 |
2019 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment.
|
30640563 |
2019 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas.
|
18464244 |
2008 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We conclude that the cell surface expression of Her-2 and EGFR and the nuclear localization of the activated p80 fragment of Her-4 suggest that all three may be contributing to osteosarcoma pathogenesis.
|
15026342 |
2004 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the role of EGFR and HER-2 expression in osteosarcoma survival remains controversial and no previous study has simultaneously investigated the association of the expression of all the four HER family members with the prognostic significance of osteosarcoma.
|
30008917 |
2018 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, we transfected EGFR and EGFR DEL (mutation with miR-141 binding site) in osteosarcoma cells, and detected the effects of miR-141 on cell proliferation, apoptosis, migration and related proteins.
|
30104888 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-337-5p participates in the development and progression of osteosarcoma via ERBB, MAPK and VEGF pathways.
|
30229817 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the interaction of EGFR aptamers and EGFR is a potential approach to promote the effective delivery of salinomycin to osteosarcoma.
|
29399118 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined that AREG increases the expression of intercellular adhesion molecule-1 (ICAM-1) through PI3K/Akt signaling pathway via its interaction with the epidermal growth factor receptor, thus resulting in the enhanced cell migration of osteosarcoma.
|
26503469 |
2015 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nutlin-3 induced the phosphorylation of EGFR, MAPK/ERK kinase (MEK)1/2 and extracellular signal-regulated kinase (ERK)1/2 in U2OS human osteosarcoma cells harboring wild-type p53.
|
23314357 |
2013 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As epidermal growth factor receptor (EGFR) positively correlates with TNM (tumor-node-metastasis) stage in osteosarcoma, EGFR may play an important role in its progression.
|
29751634 |
2018 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in osteosarcoma.
|
27830833 |
2016 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Given the relevance of epidermal growth factor receptor pathway to breast cancer and the finding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further.
|
24924174 |
2014 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seventeen (28.33%), 15 (25.00%) and 15 (25.00%) osteosarcoma specimens presented with amplification of EGFR, ErbB3 and ErbB4 gene, respectively, which were significantly higher compared with non-neoplastic bone tissues.
|
31663373 |
2019 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GAK appears to be essential for cell death because co-administration of gefitinib and luteolin to EGFR-deficient U2OS osteosarcoma cells also had a greater effect on cell viability than administration of either compound alone.
|
24971999 |
2014 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that TGF-α/EGFR interaction elicits PI3K and Akt activation, which in turn activates NF-κB, resulting in the expression of ICAM-1 and contributing the migration of human osteosarcoma cells.
|
24685520 |
2014 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the gene expression levels of three known targets in advanced gastric cancer, epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and N-methyl-N-nitrosoguanidine human osteosarcoma transforming gene (MET), using the nCounter® assay (NanoString Technologies, Seattle, WA, USA) and compared these results with protein overexpression, detected by immunohistochemistry, to evaluate the performance of this new technology.
|
25445175 |
2015 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we reported significant lower level of miR-143 and significant levels of phosphorylated EGFR and MMP9 in the resected OS from the patients, compared to the adjacent normal tissue.
|
25227664 |
2014 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas.
|
18464244 |
2008 |